Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

BeenTiktak, AMM;Williams, I.;Vrehen, HM;Richens, J;Borleffs, JCC;et.al.
(1996) Antimicrobial Agents and Chemotherapy — Vol. 40, n° 11, p. 2664-2668 (1996)

Files

No attached file found for this publication.

Details

Authors
  • BeenTiktak, AMM
    Author
  • Williams, I.
    Author
  • Vrehen, HM
    Author
  • Richens, J
    Author
  • Borleffs, JCC
    Author
Show more
Abstract
Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4(+) cell counts of between 200 and 750 cells per mm(3). Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4(+) cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

BeenTiktak, A., Williams, I., Vrehen, H., Richens, J., Aldam, D., vanLoon, A., Loveday, C., Boucher, C., Ward, P., Weller, I., & Borleffs, J. (1996). Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. Antimicrobial Agents and Chemotherapy, 40(11), 2664-2668. https://hdl.handle.net/2078.5/143643 (Original work published 1996)